Dogwood Therapeutics (DWTX) Q3 2024 earnings summary

Executive summary

• Completed business combination in October 2024, integrating Virios Therapeutics and Pharmagesic Holdings to form Dogwood Therapeutics, expanding the pipeline to three late-stage assets targeting pain and fatigue-related disorders.

• Focused on developing non-opioid pain therapies (Halneuron®) and antiviral combinations (IMC-1, IMC-2) for pain and fatigue-related disorders.

• Strategic financing of $19.5 million arranged, with $16.5 million received and $3 million expected in Q1 2025, providing working capital of approximately $23 million to fund operations and clinical milestones through 2025.

• No revenue generated; company remains in development stage with ongoing clinical trials and R&D activities.

Financial highlights

• Net loss for Q3 2024 was $2.3 million ($2.05 per share), compared to $1.2 million ($1.62 per share) in Q3 2023, reflecting higher R&D and G&A expenses due to the business combination.

• Cash balance as of September 30, 2024, was approximately $2 million; $16.5 million in loan proceeds received in October 2024.

• Accumulated deficit reached $66.1 million as of September 30, 2024.

• Net cash used in operating activities for the nine months ended September 30, 2024 was $2.66 million, compared to $3.40 million in the prior year period.

• Operating expenses increased to $2.30 million in Q3 2024 from $1.27 million in Q3 2023, driven by higher R&D and G&A costs.

Outlook and guidance

• Funding, including the pending $3 million, is projected to support operations and key clinical milestones through 2025, but management plans to seek additional financing beyond 2025.

• Top-line results from the Long COVID Phase 2a study expected mid-November 2024; Halneuron® Phase 2b interim analysis anticipated in 2H 2025.

• IMC-1 is ready for Phase 3 development in fibromyalgia, with FDA agreement on trial design and partnership discussions ongoing.

• Substantial doubt exists about the ability to continue as a going concern without further funding.

• Form 8-K/A with combined financials to be filed mid-December 2024.